CONTRASTING EFFECTS OF 17 BETA-ESTRADIOL ON THE GROWTH OF HUMAN OVARIAN-CARCINOMA CELLS IN-VITRO AND IN-VIVO

被引:43
作者
LANGDON, SP
RITCHIE, A
YOUNG, K
CREW, AJ
SWEETING, V
BRAMLEY, T
HILLIER, S
HAWKINS, RA
TESDALE, AL
SMYTH, JF
MILLER, WR
机构
[1] UNIV EDINBURGH, DEPT OBSTET & GYNAECOL, EDINBURGH EH3 9EW, SCOTLAND
[2] ROYAL EDINBURGH & ASSOCIATED HOSP, DEPT SURG, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND
关键词
D O I
10.1002/ijc.2910550323
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A human ovarian adenocarcinoma cell line (PE04) has been established as a xenograft in nude mice. In vitro, this cell line is estrogen receptor (ER)-positive and its growth is stimulated by 17 beta-estradiol at concentrations between 10(-12) and 10(-6) M. When xenografted, PE04 cells remain ER-positive and also possess progesterone receptors (PR); treatment with 17 beta-estradiol reduces the concentration of ER and increases levels of PR. Growth of the xenograft is reduced in ovariectomized animals while implantation of estrogen pellets also results in growth inhibition. Similar treatment with estrogen does not inhibit the ER-negative HOX 60 ovarian xenograft, and stimulates growth of the ER-positive ZR-75-1 breast carcinoma xenograft. Serum measurements of 17 beta-estradiol confirm that ovariectomy reduces the level of 17 beta-estradiol while implantation of estrogen pellets results in raised levels of the hormone. Tamoxifen inhibits growth of the PE04 xenograft but not that of the HOX 60 xenograft, consistent with ER status. These results indicate that ER-positive PE04 ovarian cancer cells are sensitive to 17 beta-estradiol in vivo but that the response may be of a different type from the in vitro response. This lends further support to the concept that ovarian cancer may be hormone-sensitive and potentially responsive to endocrine therapy. (C) 1993 Wiley-Liss, Inc.
引用
收藏
页码:459 / 464
页数:6
相关论文
共 35 条
[1]  
BIZZI A, 1988, CANCER RES, V48, P6222
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]  
BRANDES LJ, 1983, CANCER RES, V43, P2831
[4]   EFFECT OF TAMOXIFEN ON THE RECEPTOR-POSITIVE T61 AND THE RECEPTOR-NEGATIVE T60 HUMAN-BREAST CARCINOMAS GROWN IN NUDE-MICE [J].
BRUNNER, N ;
SPANGTHOMSEN, M ;
VINDELOV, L ;
WOLFF, J ;
ENGELHOLM, SA .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (11) :1349-1354
[5]  
CAMPBELL JJ, 1985, MED PEDIATR ONCOL, V13, P150
[6]   OVARIAN-CARCINOMA - HISTOLOGIC AND CLINICAL CORRELATION OF CYTOPLASMIC ESTROGEN AND PROGESTERONE BINDING [J].
CREASMAN, WT ;
SASSO, RA ;
WEED, JC ;
MCCARTY, KS .
GYNECOLOGIC ONCOLOGY, 1981, 12 (03) :319-327
[7]   MITOGENIC EFFECTS OF EPIDERMAL GROWTH-FACTOR AND TRANSFORMING GROWTH FACTOR-ALPHA ON EGF-RECEPTOR POSITIVE HUMAN OVARIAN-CARCINOMA CELL-LINES [J].
CREW, AJ ;
LANGDON, SP ;
MILLER, EP ;
MILLER, WR .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :337-341
[8]   INDUCTION OF EPIDERMAL GROWTH FACTOR-RELATED POLYPEPTIDES BY 17-BETA-ESTRADIOL IN MCF-7 HUMAN-BREAST CANCER-CELLS [J].
DICKSON, RB ;
HUFF, KK ;
SPENCER, EM ;
LIPPMAN, ME .
ENDOCRINOLOGY, 1986, 118 (01) :138-142
[9]   A COMPARISON OF THE EFFECTS ON FOLLICULAR DEVELOPMENT BETWEEN CLOMIPHENE CITRATE, ITS 2 SEPARATE ISOMERS AND SPONTANEOUS CYCLES [J].
GLASIER, AF ;
IRVINE, DS ;
WICKINGS, EJ ;
HILLIER, SG ;
BAIRD, DT .
HUMAN REPRODUCTION, 1989, 4 (03) :252-256
[10]  
HAMERLYNCK J, 1985, 3RD P ECCO STOCKH, V43